ADAKVEO

This brand name is authorized in Austria, Brazil, Estonia, Finland, France, Ireland, Israel, Lithuania, Poland, United Kingdom, United States

Active ingredients

The drug ADAKVEO contains one active pharmaceutical ingredient (API):

1 Crizanlizumab UNII L7451S9126 - CRIZANLIZUMAB

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1. Read about Crizanlizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ADAKVEO Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B06AX01		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 526520070096307
Country: EE	Ravimiamet	Identifier(s): 1831441
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 181522
Country: FR	Base de données publique des médicaments	Identifier(s): 62004984
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 396539
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8757
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091344
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100446201
Country: US	FDA, National Drug Code	Identifier(s): 0078-0883